A B S T R AC T
Background. Shiga toxin-producing, enteroaggregative Escherichia coli was responsible for the 2011 outbreak of haemolytic uraemic syndrome (HUS). The present single-centre, observational study describes the 1-year course of the disease with an emphasis on kidney function. Outcome data after 1 year are associated with treatment and patient characteristics at onset of HUS. Methods. Patients were treated according to a standardized approach of supportive care, including a limited number of plasmapheresis. On top of this treatment, patients with severe HUS (n = 35) received eculizumab, a humanized anti-C5 monoclonal antibody inhibiting terminal complement activation. The per-protocol decision-to start or omit an extended therapy with eculizumab accompanied by azithromycinseparated the patients into two groups and marked Day 0 of the prospective study. Standardized visits assessed the patients' well-being, kidney function, neurological symptoms, haematological changes and blood pressure.
Results. Fifty-six patients were regularly seen during the followup. All patients had survived without end-stage renal disease. Young(er) age alleviated restoring kidney function after acute kidney injury even in severe HUS. After 1 year, kidney function was affected with proteinuria [26.7%; 95% confidence interval (CI) 13.8-39.6], increased serum creatinine (4.4%, CI 0.0-10.4), increased cystatin C (46.7%, CI 32.1-61.3) and reduced (<90 mL/ min) estimated glomerular filtration rate (46.7%, CI 32.1-61.3). Nine of the 36 patients without previous hypertension developed de novo hypertension (25%, CI 10.9-39.1). All these patients had severe HUS. Conclusions. Although shiga toxin-producing Escherichia coli (STEC)-HUS induced by O104:H4 was a life-threatening acute disease, follow-up showed a good recovery of organ function in all patients. Whereas kidney function recovered even after longer duration of dialysis, chronic hypertension developed after severe HUS with neurological symptoms and could not be prevented by the extended therapy.
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I N T R O D U C T I O N
Shiga toxin-producing Escherichia coli O104:H4 (STEC) caused an outbreak of haemolytic uraemic syndrome (HUS) in Germany in May 2011 [1] . Strain typing revealed multiple risk factors explaining the high virulence and, in consequence, high incidence of HUS (22%, overall mortality 4%) [2] [3] [4] . Fenugreek sprouts were found to be responsible for bacterial spread [5, 6] . Three thousand eight hundred and sixteen STEC-infected patients and 855 cases of HUS were registered by German authorities [7] . Possibly due to different predilections in sprout consumption, the occurrence of HUS was higher in adults (89% of all cases) than in children. In children, mortality was lower (1.2%) and clinical features were comparable with previous series, with 25 .5% suffering from severe neurological symptoms [8, 9] . In adults, the short-term course of this outbreak revealed a high prevalence of neurological dysfunction (48%, 104/217 patients) [10] , need for renal replacement therapy (54-57%, i.e. 160/298 patients [11] and 281/491 patients [12] ) and mechanical ventilation (18-23%, i.e. 54/298 patients [11] and 114/491 patients [12] ). Cognitive impairment occurring in up to 67.3% of adult patients not only lead to neurological symptoms including aphasia, ataxia, paraplegia and seizures [10] but also included acute psychiatric symptoms such as hallucinations, and emotional disturbances with severe panic attacks, as reported from one centre (18/31 patients) [13] . Since the bacterial pathogen was also transferred outside of Germany (through travelling), five patients were reportedly found in Denmark and nine in France [6, 14] .
The O104:H4 bacterial pathogens induced HUS with thrombocytopenia, fragmentation of red blood cells and acute brain and kidney injury. Thrombotic microangiopathy has been shown to result from direct cytotoxic effects of shiga toxin and complement activation, which has led to different therapeutic approaches [15, 16] .
Treatment algorithms in the massive outbreak was based on best supportive care and plasmapheresis but varied among the different centres. The German Society of Nephrology published treatment suggestions and recommended withholding of antibiotics [17] . In cases of severe HUS, the administration of eculizumab, a humanized anti-C5 monoclonal antibody inhibiting terminal complement activation, was recommended [17] , based on a report describing a positive outcome in three children with severe neurological HUS [18] . Whether this therapy may prevent loss of organ function remains unclear, because an epidemicwide, randomized, controlled study could not be performed.
At our centre, patients were treated according to a standardized centre-specific algorithm (see MATERIALS AND METHODS): with a limited number of plasmapheresis andin cases of severe HUS-extended treatment with eculizumab accompanied by the antibiotic azithromycin (for prevention of meningococcal infection).
The present observational study compared these two groups of patients (i) during the acute phase via a retrospective data analysis and (ii) a prospective follow-up. Most importantly, the 1-year outcome of the patients' kidney function, i.e. proteinuria, creatinine, cystatin C, estimated glomerular filtration rate (eGFR) and development of hypertension, was evaluated.
M AT E R I A L S A N D M E T H O D S

Patients
Patients from our district (University Hospital of SchleswigHolstein Campus Lübeck and the Sana Hospital Lübeck) who met the criteria for HUS {acute STEC infection, as confirmed by cultural or molecular diagnosis at least once between May and July 2011, and two positive signs out of the following: haemolytic anaemia [i.e. increased lactate dehydrogenase (LDH), free haemoglobin or fragmented red blood cells and anaemia], thrombocytopenia (<150 000/μL) and acute kidney injury (AKI)} were observed in the present study. Patients gave written informed consent for the retrospective and prospective part of the study. The study was approved by the Institutional Review Board of the University of Lübeck (11-103, 11-120, 11-112) . Eculizumab was provided by its manufacturer Alexion for compassionate use without any influence on patient recruitment or treatment allocation (EudraCT No.: 2011-002691-17).
Acute treatment of HUS Treatment included best supportive care and the use of a limited number of plasmapheresis (up to five, against fresh frozen plasma). Extended treatment (ET) with eculizumab and azithromycin was recommended in cases of severe HUS, i.e. (i) appearance of neurological symptoms (such as focal or generalized seizures, paralytic symptoms, cognitive impairment with ataxia or aphasia) or (ii) persisting AKI (AKIN Grade 2) or thrombocytopenia after five treatments with plasmapheresis and administered after the patient's consent. Diagnosing (via clinical and laboratory data) and treating HUS was performed per protocol during standardized ward rounds. In cases of HUS without severe neurological symptoms and with improving renal and haematological functions after a maximum of five treatments with plasmapheresis, treatment was not extended (NET). Treatment allocation marked Day 0 of the prospective long-term study. Eculizumab was administered for 8 weeks [intravenous infusions, with the following weekly dosing: 900 mg (four doses), then 1200 mg; afterwards 1200 mg every 2 weeks, wash-out by plasmapheresis was prevented as treatment with eculizumab started after plasmapheresis]. Thereafter, a re-evaluation took place; the drug (1200 mg) could be administered another four times in cases of prolonged kidney injury. For prevention of meningococcal infection during treatment with eculizumab [19] , antibiotic prophylaxis with azithromycin (at an oral dose of 500 mg on Days 1-3 and then 250 mg every other day for 14 days for eradicating nasal and oropharyngeal bacterial colonization) and subcutaneous vaccination with a polyvalent polysaccharide vaccine against Neisseria meningitides group A,C,W135,Y were combined, as recommended by the German Society of Infectious Diseases.
Follow-up and data collection
At standardized visits (Figure 1 ), blood and urine samples (spot urine) were taken to evaluate kidney function ( proteinuria, creatinine, cystatin C and eGFR) and haematological signs (haemoglobin, platelets, leucocytes, LDH). Patients with neurological signs were examined by a neurologist. Stool samples to determine STEC positivity were taken at hospital admission, then repeated until negative. Maximal values of LDH (LDH-MAX), creatinine (creatinine-MAX) and minimal platelet count ( platelets-MIN) of each patient before Day 0 were retrospectively assessed from daily measurements. Creatinine was measured according to the Jaffé method ( pathological range >110 μmol/L for males; >98 μmol/L for females) and cystatin C was measured by assays from Abbott Laboratories via quantitative immunoturbidimetric determination (analyser: Architect ® ; pathological range: >0.99 mg/mL for females, >0.79 mg/mL for males). Proteinuria was characterized by a selective loss of albumin, quantified via nephelometric turbidometry (assay: Behring ® ) and extrapolated to the volume collected (albuminuria mg/L, normal range <30 mg/L); albuminuria was standardized per gram creatinine. eGFR was calculated according to Levey's Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [20] .
Data on the patients' history, drug intake, adverse events, physical examination and blood pressure were recorded. Patients were defined to be hypertensive, if they had to be treated with antihypertensive medication according to the current guidelines of the European Society of Hypertension. Body mass index (BMI) and number and duration of medical treatments were registered.
Statistical analysis
Demographic and clinical data of the study population are described by number of patients and percentage (categorical data) or by mean and SD (continuous data). Differences between the ET and the NET groups were assessed by chi-square tests for categorical variables or t-tests for continuous variables.
Exploratory t-tests and Fisher tests were run to analyse potential differences in the clinical parameters between groups with late effects 1 year after HUS diagnosis (such as proteinuria, increased creatinine, increased cystatin C, decreased eGFR and newly developed hypertension). All analyses were conducted with IBM SPSS Statistics 21.
R E S U LT S
Patients Fifty-six adult HUS patients (67.9% females) took part in the study (Figure 1 ). Thirty-five patients had ET. Baseline characteristics upon admission did not differ between the two groups ( Table 1) .
One solid organ kidney transplant patient (aged 59 years) was excluded from the study, and one 86-year-old patient requested limited therapy and died before Day 0. Two patients (aged 74 and 38 years) did not want to attend the visits. After 1 year, some patients cancelled their visit due to being fully recovered and at work, they were interviewed by phone.
In-hospital characteristics and treatments
The interval from hospital admission to treatment allocation at Day 0 was 8 days (median) in both groups. ET patients had severe neurological symptoms and higher laboratory risk markers before Day 0. Altogether they had a longer hospital stay, and more intense treatments, including stay on ICU, ventilation, haemodialysis and blood transfusions. Twenty-six ET (one NET) patients had been treated with anticonvulsants (median duration 32 days, mean 47 ± 41 days). All but two patients (one from each group) were treated with plasmapheresis (ET: 4.2 ± 1.3; NET: 3.8 ± 1.2 mean treatments prior to Day 0). Twenty-five patients needed renal replacement therapy due to AKI (22 ET and 3 NET) ( Table 2) .
Thirty-five patients were treated with eculizumab (four doses of 900 mg and three doses of 1200 mg). One patient decided to terminate treatment after four doses since he showed full recovery. Two patients with impaired kidney function had a prolonged treatment (another four doses of 1200 mg). Azithromycin was administered as scheduled. The mean duration of STEC carriage was significantly shorter in the ET group (17.4 ± 12.2 days versus 36.5 ± 23.6 NET, P < 0.01). ET was accompanied by moderate leucopenia in two cases.
F I G U R E 1 : Observatory trial profile and flow diagram of participants. Numbers of patients presenting at the single visits are indicated. After 1 year, some patients (number in parenthesis) did not want to continue their visits for reasons of recovered health and long distance to the outpatient clinics, but consented to telephone interviews and reviewing their laboratory charts. 
Prospective follow-up
Haematological and neurological symptoms recovered during the first weeks (Figure 2, Supplementary Table S1 ). Starting from 2 months after onset of HUS, 78.2% of all patients had hair loss that resolved within 2-5 months, with no significant difference between the treatment groups. Kidney functions gradually improved with mean creatinine returning to normal and albuminuria resolving in 40% (ET) versus 78.9% (NET) after 8-12 weeks (Figures 2 and 3 ). Blood pressure was treated on the basis of the patients' blood pressure protocols, and antihypertensive medications were adapted during the visits. The office blood pressure measurements and the antihypertensive drugs are 
O R I G I N A L A R T I C L E
S e q u e l a e o f h a e m o l y t i c u r e m i c s y n d r o m e a f t e r S T E C i n f e c t i o n given in Supplementary Table S2 . After 1 year, 51 patients were interviewed, and 45 of 56 (80.4%) attended the visit. Renal end points revealed a similar percentage of mild to moderate chronic kidney disease (CKD) in both groups (Table 3) . Mean serum creatinine was in the normal range, except for two ET patients (maximum: 129 μmol/L).
Twelve of 45 patients (26.7%) still had proteinuria. During acute HUS, they had higher severity markers (LDH-MAX: 1502 U/L versus 1064 U/L, P = 0.037, and creatinine-MAX: 500 μmol/L versus 298 μmol/L, P = 0.025) and a longer duration of dialysis (19 versus 11 days, P = 0.018).
The mild increase of cystatin C (in 21 of 45 patients, 46.7%) was associated with a high creatinine-MAX before Day 0 (P = 0.039). In parallel, eGFR was reduced in 46.7%. In five patients, eGFR was below 60 mL/min (three ET: 58.5-59.5 mL/min and two NET: 43.7-59.2 mL/min). The decrease in eGFR (<90 mL/min) was strongly associated with age (60 versus 43 years, P = 0.000) and a higher number of plasmapheresis (5 versus 4, P = 0.031).
Hypertension persisted in nine patients, i.e. 25% of the previously non-hypertensive patients. All of them were ET patients with severe HUS, i.e. neurological symptoms (P < 0.014), severe thrombocytopenia (23 300/μL versus 38 100/μL, P < 0.02) and higher LDH (1723 versus 1147 U/mL, P = 0.06).
Five patients (four ET and one NET) recovered from hypertension during the 1-year follow-up. Comparison of clinical parameters revealed that they were younger (40 ± 11 versus 60 ± 10 years, P < 0.01). Surprisingly, their maximal creatinine levels were higher during acute HUS compared with the 24 patients who stayed hypertensive (558 ± 140 versus 288 ± 199 μmol/L, P < 0.01).
D I S C U S S I O N
This observational trial describes the long-term outcome of HUS from one representative district in northern Germany after the STEC outbreak in 2011. It showed a remarkably favourable 1-year outcome of the patients' health, revealing normal kidney function or mild CKD in both groups. However, severely ill patients developed chronic hypertension, i.e. patients with severe neurological symptoms, severe thrombocytopenia and high plasma LDH. Younger age appeared to protect patients from developing CKD and alleviated recovering from AKI.
Limitations of the present study resulted from the observational approach, which was chosen for ethical reasons, instead of a controlled randomized study. The present data cannot evaluate the benefit of treatments. No patient data have systematically been recorded before the outbreak, so blood pressure levels cannot be compared directly. Certainly, a selection bias cannot be fully ruled out: patient selection via triage created two groups with distinct severity of HUS. Compared with previous data from the outbreak, the present ET group had very severe HUS including 74% of patients treated with anticonvulsants for seizures, myoclonus and cognitive impairment with ataxia and aphasia and 63% on dialysis [10, 12, 21] .
Renal function after STEC-HUS. Based on the entire cohort (35 patients with extended therapy ET and 21 patients with non-extended therapy NET), the percentage of patients with pathological (dark grey bars) versus normal findings (bright grey bars) are given for proteinuria (<30 gm/L urine, on top), glomerular filtration rate according to the CKD-EPI formula (<90 mL/min, middle) and drug-treated hypertension (below). White bars indicate the percentage of patients who had no more pathological signs before but did not come to the indicated follow-up visit and therefore were counted as missing. Black bars mark the percentage of patients who had hypertension before Escherichia coli O104:H4 infection leading to HUS in 2011.
No severe adverse events from treatments were recorded in our cohort. Azithromycin treatment (to protect patients from meningitis during treatment with eculizumab) might have yielded additional benefit, as this antibiotic has been shown to clear enteric STEC carriage more quickly, creating an obvious bias of STEC clearing rates between the two groups [22] . Combined with eculizumab, no flare of HUS was observed during acute treatment of HUS.
Another limitation of our long-term study was the loss of adherence to visits, also reported by others [23] : of 56 patients observed within the study, 45 were examined after 1 year. As evidenced by the phone interviews, patients without pathological signs during the last months tended to drop out, leading to a loss-to-follow-up mainly in 'healthy' patients and an overreporting of pathological signs on the long.
Compared with previous case series where mortality and end-stage renal disease occurred in up to 30% [24, 25] and pooled incidence of end-stage renal disease after 1-22 years was as high as 12% [26] , the outcome of the present cohort was fairly positive. Reported data from children of the 2011 outbreak showed similar positive results: 3/90 had moderate CKD and 1/90 end-stage renal disease [9] .
HUS severity of our NET group resembled the northern German cohort [11] (298 adults, maximal LDH 932 U/L and creatinine 203 μmol/L), from which the 8-week outcome of the outbreak had been assessed with a mortality of 4%, three patients were still on dialysis. Retrospectively validating the benefit of various treatment strategies, the HUS consortium evaluated the course of HUS to be a severe, but self-limiting acute condition: supportive strategies including volume repletion were a mainstay of successful therapy [27] [28] [29] . No shortterm benefit of plasmapheresis was found, but differences in group size and mortality confounded this comparison. Although data from controlled trials do not exist, plasmapheresis might be beneficial in severely ill patients [14, 30] . In our cohort, a substantial number of patients developed severe HUS despite prompt use of plasmapheresis, corroborating a previous observation that plasma therapy during acute phase was associated with a poor long-term outcome [23] .
While a case-control comparison of 67 adults from the HUS consortium [11] showed no benefit of eculizumab (2.9 doses, treated patients were older: 50.6 versus 42.3 years), Delmas et al. [31] described an early and efficient recovery of nine severely ill HUS patients after prompt treatment with eculizumab and antibiotics without plasmapheresis. Similar to their data, in the present study, haematological parameters and kidney function improved after administration of eculizumab and azithromycin. Although patients from the ET group had a higher HUS severity than the NET group (and, hence, the northern German cohort), all patients recovered kidney function by Day 32, and mean creatinine reached normal values after 8 weeks.
Prospective studies on the very long-term outcome of STEC-HUS are missing. Following gastroenteritis (not HUS) from E. coli O157:H7, a prospective study did not find an increased cardiovascular risk [32] . These data cannot be transferred to HUS, where future development of hypertension appears to be linked to the severity of the disease [33] . AKI by itself may increase the risk of CKD [34] . Moreover, resolved glomerular disease bears an increased risk of developing hypertension [35] . Multiorgan endothelial injury leading to thrombotic microangiopathy of the glomeruli represents typical histological signs of STEC O104:H4-induced HUS. In addition, shiga toxin 2-induced HUS has recently been shown to induce AKI due to acute tubular damage [36] .
In the brain, shiga toxin 2 has been shown to induce neuronal apoptosis and inflammatory responses [37] . Another study found that these damages might be rescued by dexamethasone [38] . As hypertension developed in our patients with neurological symptoms, it might be speculated that hypertension represented a residue of brain injury via endothelial damage from acute STEC infection that could not be alleviated by our treatments. In the present O104:H4 outbreak, severe neurological symptoms have been associated with cerebral multistructural changes in quantitative MRI, suggesting a toxicmetabolic pathology behind the neurological impairment rather than multiple infarction due to microthrombosis [39] .
The STEC-induced neurological symptoms including cognitive impairment with aphasia or epileptic seizures were accompanied by symmetrical hyperintensities in the region of abducens nucleus and lateral thalamus and have been described as 'neuro-STEC', due to the neurotropism of the hypervirulent O104:H4 variant of STEC [10, 40] . Although 'neuro-STEC' resolved within 6 months in 97% of patients, these patients should be screened for hypertension in view of the present data and a long-term survey appears to be mandatory.
Outcomes after bacterial HUS in children have improved over the years and patients without proteinuria, hypertension and an eGFR > 80 mL/min seem to have an excellent prognosis. But most of the patients progressing to end-stage renal failure did not recover normal renal function. Duration of anuria (more Table 3 . Proportion of patients with late effects 1 year after diagnosis of HUS. n = number of patients with pathological signs. Pathological categories were as follows: creatinine >98 μmol/L (females), >110 μmol/L (males), proteinuria >30 mg albumin/L urine, cystatin C >0.99 mg/mL (females), >0.79 mg/mL (males) and eGFR according to the CKD-EPI formula (eGFR) < 90 mL/min. N = number of cases who were examined after 1 year (C ave : 15 patients had hypertension before they got ill with HUS). Outcome is shown for the two groups: ET with severe HUS and extended treatment and NET with HUS and no extended treatment. Late differences occurred in newly developed hypertension, P < 0.05, according to Fisher's exact test.
than 10 days) and prolonged haemodialysis were the most important risk factors for the poor renal outcome [26, 41] . Different from the present study, end-stage renal failure on the long term was found in 12-60% of the patients [31, 42] . After 9.6 years, hypertension, proteinuria and a reduced kidney function had occurred in 24 out of 61 young patients examined [43] . Compared with those historic studies, the outcome of our intensely treated group showed clear improvement. However, it should be mentioned that late sequelae may still appear after this first year, as published before [23] , so that a continuing survey appears to be mandatory. Moreover, the present 1-year follow-up suggests that a young (er) age helps to restore kidney function after AKI even in severe HUS. These findings accord with registry data from bacterial HUS, showing increased mortality with an older age [25] . Against this background, the adult survivors of the 2011 STEC-HUS outbreak regained a favourable clinical status.
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